CDCP1 (CUB domain containing protein 1) is a potential urine-based biomarker in the diagnosis of low-grade urothelial carcinoma
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0281873 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Chien-Liang Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Urology, Department of Surgery, Chi Mei Medical Center, Tainan, Taiwan. Hauptthemen laut MEDLINE: Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Body Fluids. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Technology, Chi Mei Medical Center.
Abstract (Originalsprache)
Urine-based cytology is non-invasive and widely used for clinical diagnosis of urothelial carcinoma (UC), but its sensitivity is less than 40% for low-grade UC detection. As such, there is a need for new diagnostic and prognostic biomarkers of UC. CUB domain containing protein 1 (CDCP1) is a type I transmembrane glycoprotein highly expressed in various cancers. Using tissue array analysis, we demonstrated that CDCP1 expression in UC patients (n = 133), especially in those with low-grade UC, was significantly higher than in 16 normal persons. In addition, CDCP1 expression in urinary UC cells could also be detected by using immunocytochemistry method (n = 11). Furthermore, in 5637-CD cells, overexpression of CDCP1 affected the expression of epithelial mesenchymal transition-related markers and increased matrix metalloproteinase 2 expression and migration ability. Conversely, the knockdown of CDCP1 in T24 cells had the opposite effects. Using specific inhibitors, we demonstrated the involvement of c-Src/PKCδ signaling in the CDCP1-regulated migration of UC. In conclusion, our data suggest that CDCP1 contributes to the malignant progression of UC and may have the potential as a urine-based biomarker for detecting low-grade UC. However, a cohort study needs to be conducted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Urology, Department of Surgery, Chi Mei Medical Center, Tainan, Taiwan.
- Department of Pathology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
- Department of Medical Research, Chi Mei Medical Center, Tainan, Taiwan.
- Department of Medical Laboratory Science and Biotechnology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
ORCID-Profile: Ching-Ping Chang, Yu-Hao Chang, Huei-Sheng Huang
Förderung
- Ministry of Science and Technology
- Chi Mei Medical Center
Zitieren
APA
Liu, C. L., Tsai, H. W., Peng, S. L., Chang, C. P., Chang, Y. H., & Huang, H. S. (2023). CDCP1 (CUB domain containing protein 1) is a potential urine-based biomarker in the diagnosis of low-grade urothelial carcinoma. PLOS ONE. https://doi.org/10.1371/journal.pone.0281873
Vancouver
Liu CL, Tsai HW, Peng SL, Chang CP, Chang YH, Huang HS. CDCP1 (CUB domain containing protein 1) is a potential urine-based biomarker in the diagnosis of low-grade urothelial carcinoma. PLOS ONE. 2023. doi:10.1371/journal.pone.0281873
BibTeX
@article{Liu2023,
author = {Liu, Chien-Liang and Tsai, Hung-Wen and Peng, Shu-Ling and Chang, Ching-Ping and Chang, Yu-Hao and Huang, Huei-Sheng},
title = {CDCP1 (CUB domain containing protein 1) is a potential urine-based biomarker in the diagnosis of low-grade urothelial carcinoma},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0281873}
}
EUVIMED